EUVIMEDEUVIMED entdecken
Vergleichsstudie

Cost-utility analysis of the use of a wearable cardioverter defibrillator (LifeVest®) versus standard of care in the prevention of sudden cardiac death in patients after myocardial infarction

Przemysław Mitkowski, Maciej Sterliński, Marcin Czech, Andrzej Przybylski, Jerzy K Wranicz, Maciej Kempa, Jarosław Kaźmierczak, Marcin Michalak, Paweł Ptaszyński, Adam Sokal, Marek Gierlotka, Robert J Gil und 12 weitere

Polish Heart Journal · 2025

DOI: 10.33963/v.phj.108491 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Polish Heart Journal, 2025. Verfasst von Przemysław Mitkowski und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Poznan University of Medical Sciences, Poznań, Poland. dominik.golicki@wum.edu.pl. Hauptthemen laut MEDLINE: Death, Sudden, Cardiac, Myocardial Infarction, Wearable Electronic Devices, Defibrillators. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Each year, approximately 350 000 cases of out-of-hospital sudden cardiac arrest occur in Europe. The Vest Prevention of Early Sudden Death Trial (VEST) demonstrated the effectiveness and safety of the wearable cardioverter defibrillator (WCD) in preventing sudden cardiac death (SCD). Recent findings from a retrospective registry of Polish patients prescribed with the WCD further validated its efficacy in real-world settings. AIMS: To assess the cost-effectiveness of using the LifeVest® WCD compared to standard of care for preventing SCD in post-myocardial infarction patients in Poland. MATERIAL AND METHODS: Cost-effectiveness and cost-utility analyses were conducted from the perspective of the Polish public payer, the National Health Fund. A Markov model, reflecting current clinical practice, was utilized, incorporating data from the Vest Prevention of Early Sudden Death Trial, Polish healthcare costs, and health state utilities based on Polish norms. The analysis employed a lifetime horizon. One-way deterministic and probabilistic sensitivity analyses were performed to gauge parameter uncertainty. Results were compared against the official cost-effectiveness threshold in Poland. RESULTS: Sudden cardiac death prevention with WCD incurred additional costs of 51 300 PLN (12 100 EUR) compared to standard of care but resulted in gains of 0.49 life years and 0.39 quality-adjusted life years (QALYs). The incremental cost-utility ratio was 132 400 PLN/QALY (31 100 EUR/QALY), nearly 40% below the cost-effectiveness threshold. Sensitivity analyses confirmed the robustness of these findings. CONCLUSIONS: The strategy of preventing SCD through WCD usage proves to be cost-effective within the Polish healthcare context. The clinical benefits derived from WCD use justify the additional costs incurred, making it a viable option for SCD prevention in post-myocardial infarction patients in Poland.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Death, Sudden, CardiacMyocardial InfarctionWearable Electronic DevicesDefibrillatorsStandard of CareHumansCost-Benefit AnalysisPolandMaleFemaleMiddle AgedAgedQuality-Adjusted Life Years

Stichwörter der Autor:innen

cost-effectiveness analysiscost-utility analysismyocardial infarctionsudden cardiac deathwearable cardioverter defibrillator

Autor:innen und Institutionen

  • Department of Cardiology, Poznan University of Medical Sciences, Poznań, Poland. dominik.golicki@wum.edu.pl.
  • 1st Department of Arrhythmia, The Cardinal Stefan Wyszynski National Institute of Cardiology, Warszawa, Poland.
  • Department of Pharmacoeconomics, Institute of Mother and Child, Warszawa, Poland.
  • Business School, Warsaw University of Technology, Warszawa, Poland.
  • Department of Cardiology with the Acute Coronary Syndromes Subdivision, Clinical Provincial Hospital No. 2, Rzeszów, Poland.
  • Faculty of Medicine, University of Rzeszow, Rzeszów, Poland.

Zitieren

APA

Mitkowski, P., Sterliński, M., Czech, M., Przybylski, A., Wranicz, J. K., Kempa, M., Kaźmierczak, J., Michalak, M., Ptaszyński, P., Sokal, A., Gierlotka, M., Gil, R. J., Farkowski, M. M., Kowalski, O., Pawlak, A., Szumowski, Ł., Tajstra, M., Witkowski, A., Wojtaszczyk, A., …, & Golicki, D. (2025). Cost-utility analysis of the use of a wearable cardioverter defibrillator (LifeVest®) versus standard of care in the prevention of sudden cardiac death in patients after myocardial infarction. Polish Heart Journal. https://doi.org/10.33963/v.phj.108491

Vancouver

Mitkowski P, Sterliński M, Czech M, Przybylski A, Wranicz JK, Kempa M, et al. Cost-utility analysis of the use of a wearable cardioverter defibrillator (LifeVest®) versus standard of care in the prevention of sudden cardiac death in patients after myocardial infarction. Polish Heart Journal. 2025. doi:10.33963/v.phj.108491

BibTeX
@article{Mitkowski2025,
  author = {Mitkowski, Przemysław and Sterliński, Maciej and Czech, Marcin and Przybylski, Andrzej and Wranicz, Jerzy K and Kempa, Maciej and Kaźmierczak, Jarosław and Michalak, Marcin and Ptaszyński, Paweł and Sokal, Adam and Gierlotka, Marek and Gil, Robert J and Farkowski, Michał M and Kowalski, Oskar and Pawlak, Agnieszka and Szumowski, Łukasz and Tajstra, Mateusz and Witkowski, Adam and Wojtaszczyk, Adam and Ząbek, Andrzej and Dobrowolska, Iwona and Młyńczak, Katarzyna and Niewada, Maciej and Golicki, Dominik},
  title = {Cost-utility analysis of the use of a wearable cardioverter defibrillator (LifeVest®) versus standard of care in the prevention of sudden cardiac death in patients after myocardial infarction},
  journal = {Polish Heart Journal},
  year = {2025},
  doi = {10.33963/v.phj.108491}
}
Kostenlos starten →